Inimmune
Business Services · Montana, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1121 E Broadway St Ste 106, Missoula, Mo...Phone Number
(406) 541-5913Website
www.inimmune.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Inimmune
Inimmune is a clinical-stage biotech company dedicated to discovering and developing innovative immunotherapies for cancer, allergies, autoimmunity, and vaccines. Their pipeline includes clinical-stage Toll-like receptor (TLR) agonists and various pre-clinical programs aimed at enhancing vaccine adjuvants. The company collaborates with leading universities and biotech firms to advance their research and development efforts. Inimmune's mission is to harness the immune system to improve human health through novel therapeutic solutions.Explore more
Inimmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inimmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Inimmune has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Inimmune is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Inimmune launches new products
Click to see if Inimmune had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Inimmune
Earning: See what the market has to say on Inimmune recently announced quarterly report
Inimmune, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Inimmune has new funding data
Recommended Actions
Find VP level buyers at Inimmune
Find 3 more new buyers
Compare Similar Companies to Inimmune
Compare insights from companies similar to Inimmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Inimmune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Inimmune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Inimmune.
Inimmune financials insights
Gather financial insights about Inimmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$22M
Inimmune Tech Stack
A closer look at the technologies used by Inimmune
Inimmune News & Media
Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout
Ferdinand Massari, M.D., appointed Chief Medical Officer to lead clinical strategy and pipeline advancement Ryan McMillian named Head of Financial Strategy to support corporate strategy and long-term growth MISSOULA, Mont., March 5, 2026 /PRNewswire/ -- Inimmune Corporation, a...Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients
MISSOULA, Mont., Jan. 7, 2026 /PRNewswire/ -- Inimmune Corporation ("Inimmune"), a clinical-stage biotechnology company focused on developing innovative immunotherapies, today announced the start of its pivotal Phase 2 clinical trial evaluating INI-2004 in patients with allergic rhinitis....Inimmune publishes positive proof of mechanism for TLR4 Agonist INI-2004 in Allergic Rhinitis
Intranasal administration of a synthetic Toll-Like Receptor 4 (TLR4) agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization. MISSOULA, Mont., July 30, 2024 /PRNewswire/ -- Inimmune, a leading biotech company...INIMMUNE ANNOUNCES FIRST CANCER PATIENT DOSED IN PHASE 1 CLINICAL STUDY USING THE IMMUNOTHERAPEUTIC INI-4001, A NOVEL TLR7/8 AGONIST
MISSOULA, Mont., July 24, 2024 /PRNewswire/ -- Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Inimmune
Sign Up For FreeTo access detailed company insights
Inimmune is a clinical-stage biotech company dedicated to discovering and developing innovative immunotherapies for cancer, allergies, autoimmunity, and vaccines. Their pipeline includes clinical-stage Toll-like receptor (TLR) agonists and various pre-clinical programs aimed at enhancing vaccine adjuvants. The company collaborates with leading univ... Read More
